BIIB — Biogen Inc. stock price and chart

BIIB

$252.73+0.19%

as of close, Oct 27, 2026

☾ AH $252.73 +0.19%

Biogen Inc.Stock · HealthcareS&P 500 Equal Weight · 0.2% of RSPNasdaq Composite · 0.06% of ONEQS&P 500 · 0.05% of SPYRussell 1000 · 0.05% of IWBUS Stock Market · 0.04% of VTIRussell 3000 · 0.04% of IWVMSCI World · 0.03% of URTHMSCI ACWI · 0.03% of ACWI

PeersBMYGILDGSKPFEINCYSNY

Share this page

Technical analysis2

Overlay lines0

Addendum charts0

VolumeEEEEEEEEEEEEEEEEEEEEE

20162019202120242026

150.0200.0250.0300.0350.0020.0M40.0M$252.73

2026-10-27

Price$252.73

MA20$212.57

MA50$187.29

Vol5.7M

What would $1,000 invested in BIIB be worth today? →

BIIB returns: By year · By month · By week · Trailing

Key stats#

Price data

Price: $252.73
YTD price return: +43.60%
YTD total return: +43.60%
Next earnings: Oct 28, 2026 · Before open
Market cap: 37.3B2016-12 61.7B2026-10 37.3B-39.5% over the window
Enterprise value: 43.7B
Shares outstanding: 147.8M2016-06 219.1M2026-06 147.8M-32.6% over the window
52W low: $138.00
52W high: $254.41
From 52W high: -0.66%
From 52W low: +83.14%
52W range: 99%
Beta: 0.16

Volume

Rel volume: 1.10×
30D volume: 1.3M
30D $ vol: 292.8M

Insider trading

Insider net 1WNo open-market insider purchase or sale with a transaction date in the last 7 days, as filed on Form 4.: none
Insider net 1MNo open-market insider purchase or sale with a transaction date in the last 30 days, as filed on Form 4.: none
Insider net 3M0 insider-days of buying (no priced lot) and 2 of selling ($240K) in the last 91 days, by transaction date, open-market transactions only — awards, exercises, tax withholding and employee-plan purchases are not counted. A Form 4 is filed within two business days of the trade, so the newest days may not be in yet.: −$240K
Insider net 1Y1 insider-day of buying ($585) and 4 of selling ($905K) in the last 365 days, by transaction date, open-market transactions only — awards, exercises, tax withholding and employee-plan purchases are not counted. A Form 4 is filed within two business days of the trade, so the newest days may not be in yet.: −$905K

Form 4 transactions by trade date, as filed; latest on file 2026-08-04.

Fundamentals

Sales (ttm): 10B2016-06 11.2B2026-06 10B-10.8% over the window
Sales/share: $67.872016-06 $51.292026-06 $67.87+32.3% over the window
EPS (ttm): $5.642016-06 $17.142026-06 $5.64-67.1% over the window
FCF (ttm): 2.7B2016-06 3.5B2026-06 2.7B-22.4% over the window
FCF/share: $18.252016-06 $15.852026-06 $18.25+15.1% over the window
Book value/share: $127.562016-06 $52.042026-06 $127.56+145.1% over the window
Net margin: 8.32%2016-06 34.0%2026-06 8.3%-75.5% over the window
ROE: 4.43%2016-06 33.5%2026-06 4.4%-86.8% over the window
ROA: 2.60%2016-06 17.7%2026-06 2.6%-85.3% over the window
Debt / equity: 0.39×2016-06 0.572026-06 0.39-32.5% over the window
Current ratio: 1.872016-06 2.962026-06 1.87-37.0% over the window

Growth (CAGR, ttm) · 10Y

Sales: +0.31%2025-06-30 → 2026-06-3010B → 10B (+0.3% total)+0.19%2023-06-30 → 2026-06-3010B → 10B (+0.6% total)-3.03%2021-06-30 → 2026-06-3011.7B → 10B (-14.3% total)-1.13%2016-06-30 → 2026-06-3011.2B → 10B (-10.8% total)
Net income: -45.49%2025-06-30 → 2026-06-301.5B → 834.6M (-45.5% total)-32.08%2023-06-30 → 2026-06-302.7B → 834.6M (-68.7% total)-15.33%2021-06-30 → 2026-06-301.9B → 834.6M (-56.5% total)-14.11%2016-06-30 → 2026-06-303.8B → 834.6M (-78.1% total)
FCF: +36.31%2025-06-30 → 2026-06-302B → 2.7B (+36.3% total)+21.58%2023-03-31 → 2026-06-301.4B → 2.7B (+88.7% total)+1.72%2021-06-30 → 2026-06-302.5B → 2.7B (+8.9% total)-2.50%2016-06-30 → 2026-06-303.5B → 2.7B (-22.4% total)
Shares: +0.78%2025-06-30 → 2026-06-30146.6M → 147.8M (+0.8% total)+0.67%2023-06-30 → 2026-06-30144.8M → 147.8M (+2.0% total)-0.17%2021-06-30 → 2026-06-30149M → 147.8M (-0.9% total)-3.86%2016-06-30 → 2026-06-30219.1M → 147.8M (-32.6% total)

Per-share growth (CAGR, ttm) · 10Y

EPS: -46.15%2025-06-30 → 2026-06-30$10.46 → $5.64 (-46.1% total)-32.52%2023-06-30 → 2026-06-30$18.35 → $5.64 (-69.3% total)-14.67%2021-06-30 → 2026-06-30$12.46 → $5.64 (-54.8% total)-10.53%2016-06-30 → 2026-06-30$17.14 → $5.64 (-67.1% total)
Sales/share: -0.46%2025-06-30 → 2026-06-30$68.19 → $67.87 (-0.5% total)-0.48%2023-06-30 → 2026-06-30$68.85 → $67.87 (-1.4% total)-2.87%2021-06-30 → 2026-06-30$78.49 → $67.87 (-13.5% total)+2.84%2016-06-30 → 2026-06-30$51.29 → $67.87 (+32.3% total)
FCF/share: +35.26%2025-06-30 → 2026-06-30$13.50 → $18.25 (+35.2% total)+20.82%2023-03-31 → 2026-06-30$9.87 → $18.25 (+84.9% total)+1.90%2021-06-30 → 2026-06-30$16.61 → $18.25 (+9.9% total)+1.42%2016-06-30 → 2026-06-30$15.85 → $18.25 (+15.1% total)
Book value/share: +6.06%2025-06-30 → 2026-06-30$120.27 → $127.56 (+6.1% total)+8.49%2023-06-30 → 2026-06-30$99.89 → $127.56 (+27.7% total)+12.08%2021-06-30 → 2026-06-30$72.14 → $127.56 (+76.8% total)+9.38%2016-06-30 → 2026-06-30$52.04 → $127.56 (+145.1% total)
Price: +68.06%2025-10-27 → 2026-10-27$150.43 → $252.73 (+68.0% total)Price appreciation from split-adjusted daily closes, excluding dividends; endpoints are exact trading-day anniversaries of the latest close.+2.52%2023-10-27 → 2026-10-27$234.52 → $252.73 (+7.8% total)Price appreciation from split-adjusted daily closes, excluding dividends; endpoints are exact trading-day anniversaries of the latest close.-0.56%2021-10-27 → 2026-10-27$259.95 → $252.73 (-2.8% total)Price appreciation from split-adjusted daily closes, excluding dividends; endpoints are exact trading-day anniversaries of the latest close.-1.58%2016-10-26 → 2026-10-27$296.46 → $252.73 (-14.8% total)Price appreciation from split-adjusted daily closes, excluding dividends; endpoints are exact trading-day anniversaries of the latest close.
Total return: +68.06%2025-10-27 → 2026-10-27$150.43 → $252.73 (+68.0% total)Total return with dividends reinvested (adjusted daily closes); endpoints are exact trading-day anniversaries of the latest close. The gap against the Price row is the dividend contribution.+2.52%2023-10-27 → 2026-10-27$234.52 → $252.73 (+7.8% total)Total return with dividends reinvested (adjusted daily closes); endpoints are exact trading-day anniversaries of the latest close. The gap against the Price row is the dividend contribution.-0.56%2021-10-27 → 2026-10-27$259.95 → $252.73 (-2.8% total)Total return with dividends reinvested (adjusted daily closes); endpoints are exact trading-day anniversaries of the latest close. The gap against the Price row is the dividend contribution.-1.58%2016-10-26 → 2026-10-27$296.46 → $252.73 (-14.8% total)Total return with dividends reinvested (adjusted daily closes); endpoints are exact trading-day anniversaries of the latest close. The gap against the Price row is the dividend contribution.

Fundamentals end at the last reported quarter; price and total return end at the latest close.

Valuation

P/E (ttm)Price ÷ TTM diluted EPS. Net income carries everything below the operating line, including one-off gains. Negative when the trailing year lost money.: 44.8×2016-12 15.882026-10 44.71+181.5% over the window
P/OI (ttm)Price ÷ TTM operating income. Excludes the below-the-line items that make P/E jump — mark-to-market gains, settlements, tax true-ups.: 15.6×2016-12 11.362022-06 12.06+6.1% over the window
Fwd P/E: 15.3×
P/S (ttm)Market cap ÷ TTM revenue.: 3.7×2016-12 5.402026-10 3.72-31.2% over the window
P/B (mrq)Market cap ÷ stockholders' equity at the most recent quarter end.: 2.0×2016-12 5.092026-10 1.98-61.1% over the window
P/FCF (ttm)Market cap ÷ TTM free cash flow (operating cash flow − capex).: 13.8×2016-12 17.002026-10 13.84-18.6% over the window
EV/EBITDA (fy): 20.4×
EV/Sales (ttm): 4.4×
FCF yield (ttm)TTM free cash flow ÷ market cap — the inverse of P/FCF.: 7.22%2016-09 5.9%2026-06 8.4%+42.7% over the window
Buyback yield (realized, 1y)1 − shares_at(2026-06-30) ÷ shares_at(2025-06-30) = 1 − 147.8M ÷ 146.6M. Point-in-time share counts from the company's own SEC filings (the same count at both ends), published only when the cash flow statement shows repurchases inside that window. A falling price can't inflate it; negative means net dilution.: -0.78%
Shareholder yield (realized, 1y)Buyback leg + dividend leg: shares retired over the year (-0.78%) + dividends paid over that year ($0) ÷ market_cap_at(2025-06-30) ($18.4B). Both legs are measured against the start of the window, so a payout can't shrink its own denominator.: -0.78%
Buyback yield (cash, ttm)Buybacks net of issuance over the trailing twelve months ($0) ÷ today's market cap ($37.3B). Dollars SPENT over what the company is worth NOW — a stock that fell after buying reads high.: 0.00%2016-09 3.8%2026-06 0.0%-100.0% over the window
Shareholder yield (cash, ttm)(TTM buybacks net of issuance $0 + TTM dividends $0) ÷ today's market cap ($37.3B). Same caveat as the cash buyback yield.: 0.00%2016-09 3.8%2026-06 0.0%-100.0% over the window

Vs own 10Y history

P/E: 100th
P/OI: 91st
P/S: 63rd
P/B: 23rd
P/FCF: 58th

Bar = where today’s multiple sits in BIIB’s own 10-year range:near a decade-low (cheap)→near a decade-high (rich).

Performance · price return · as of 2026-10-27#

+0.19%

+3.96%

+11.04%

+26.28%

YTD

+43.60%

+68.01%

-2.78%

Recent filings#

Jul 29Earnings · Earnings release — EPS $3.60 vs $3.04 est. (+18.4%); revenue $2.74B (+3% y/y) 1.8%
Jul 18-K · Results of operations

All filings and insider trades →

Financial statements

Open full BIIB financials →

Loading financial statements…

Ticker	Name	1M	1D
LLY	Eli Lilly and Company	+8.32%	+0.22%
JNJ	Johnson & Johnson	-0.92%	+0.91%
ABBV	AbbVie Inc.	+8.34%	-0.12%
UNH	UnitedHealth Group Incorporated Common Stock (DE)	+8.98%	-0.08%
MRK	Merck & Co. Inc.	-4.68%	+0.86%
NVS	Novartis AG	+7.84%	+1.98%
TMO	Thermo Fisher Scientific Inc.	+2.67%	+1.19%
AMGN	Amgen Inc.	+8.04%	+0.75%

BIIB — Biogen Inc. price, chart and key statistics